决定异体 CAR T 细胞排斥与扩增的细胞和分子机制
Cellular and molecular mechanisms determining allogeneic CAR T cell rejection and expansion.
我们评估了11例接受单一批次cemacabtagene ansegedleucel(cema-cel)治疗的大B细胞淋巴瘤患者,cemacabtagene ansegedleucel是一种异体抗CD19 CAR T产品。
英文原题:Bioconjugated liquid-like solid enhances characterization of solid tumor - chimeric antigen receptor T cell interactions.
嵌合抗原受体(CAR)T 细胞疗法作为血液系统恶性肿瘤的免疫治疗已取得显著成功,其治疗实体瘤的潜力是一个活跃的研究领域。
嵌合抗原受体(CAR)T细胞疗法在血液系统恶性肿瘤免疫治疗中取得显著成功,其治疗实体瘤的潜力也正在积极研究。然而,T细胞在肿瘤微环境(TME)中的迁移和运动能力有限,仍是实体瘤CAR-T治疗的挑战。为深入理解CAR-T在实体瘤中的功能,研究人员将CD70特异性CAR-T细胞置于生物偶联类液态固体(LLS)介质中的受限三维微通道网络,评估其免疫迁移和浸润。结果显示,CAR-T细胞可成功迁移,并对表达CD70的胶质母细胞瘤和骨肉瘤产生抗肿瘤活性。通过综合分析细胞因子和趋化因子并结合原位成像,研究阐明免疫细胞募集由趋化作用介导,且效应细胞与靶细胞比值对总体抗肿瘤功能具有重要影响。进一步通过单细胞采集和转录组分析,发现不同免疫亚群存在差异基因表达。这些结果有助于认识CAR-T细胞在实体瘤中复杂的功能动态,并为这一有前景的癌症疗法后续研究和开发提供依据。意义声明:利用CAR-T等特化免疫细胞对抗癌症,在血液肿瘤中已取得显著成功,但在脑癌或骨癌等实体瘤中尚未重现,主要原因是实体瘤存在物理屏障。目前的临床前技术尚不能可靠评估肿瘤与免疫细胞之间的相互作用。为更好研究CAR-T细胞,研究人员开发了一种创新的体外三维模型,有望在单细胞层面解析肿瘤与CAR-T细胞的相互作用。研究结果加深了对CAR-T细胞在实体瘤中复杂功能动态的理解,可为该治疗方法的进一步研究和开发提供依据。
Chimeric antigen receptor (CAR) T cell therapy has demonstrated remarkable success as an immunotherapy for hematological malignancies, and its potential for treating solid tumors is an active area of research. However, limited trafficking and mobility of T cells within the tumor microenvironment (TME) present challenges for CAR T cell therapy in solid tumors. To gain a better understanding of CAR T cell function in solid tumors, we subjected CD70-specific CAR T cells to a challenge by evaluating their immune trafficking and infiltration through a confined 3D microchannel network in a bio-conjugated liquid-like solid (LLS) medium. Our results demonstrated successful CAR T cell migration and anti-tumor activity against CD70-expressing glioblastoma and osteosarcoma tumors. Through comprehensive analysis of cytokines and chemokines, combined with in situ imaging, we elucidated that immune recruitment occurred via chemotaxis, and the effector-to-target ratio plays an important role in overall antitumor function. Furthermore, through single-cell collection and transcriptomic profiling, we identified differential gene expression among the immune subpopulations. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach. STATEMENT OF SIGNIFICANCE: The use of specialized immune cells named CAR T cells to combat cancers has demonstrated remarkable success against blood cancers. However, this success is not replicated in solid tumors, such as brain or bone cancers, mainly due to the physical barriers of these solid tumors. Currently, preclinical technologies do not allow for reliable evaluation of tumor-immune cell interactions. To better study these specialized CAR T cells, we have developed an innovative in vitro three-dimensional model that promises to dissect the interactions between tumors and CAR T cells at the single-cell level. Our findings provide valuable insights into the complex dynamics of CAR T cell function in solid tumors, informing future research and development in this promising cancer treatment approach.
MEMBER ACCOUNT
登录成功会直接打开下一页。